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ABSTRACT 
Objective: To develop precise, accurate and reproducible stability assay method by RP-HPLC for estimation of dapagliflozin in API and 
pharmaceutical dosage form. 
Methods: The adequate separation was carried using agilent C18 (4.6 ml (millimeter)*150,5 µm (micromiter), mixture of acetonitrile: di-potassium 
hydrogen phosphate with pH-6.5 adjusted with OPA (40:60 %v/v) as a mobile phase with the flow rate of 1 ml/min (milliliter/minute) and the 
effluent was monitored at 222 nm (nanometer) using photo diode array detector. The retention time of dapagliflozin API and dapagliflozin tablet 
were 3.160 min (minute) and 3.067 min (minute) respectively. 
Results: Linearity for dapagliflozin was found in the range of 50-150µg/ml (microgram/milliliter) (R2 = 0.99) respectively. The accuracy of the 
present method was evaluated at 50 %, 100% and 150%. The % recoveries of dapagliflozin API and tablet were found to be in the range of 99.00–
99.99 % and 98.50–99.99 % respectively. Precision studies were carried out and the relative standard deviation values were less than two. The 
method was found to be robust. 
Conclusion: The proposed method was found to be specific, accurate, precise and robust can be used for estimation of dapagliflozin in API and 
Pharmaceutical dosage form. 
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Dapagliflozin is chemically a (2S,3R.4R,5S,6R)-2-[4-chloro-3-(4-
ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro 2H-pyran-
3,4,5-triol) with molecular weight of 408.873 g/mol. 
Dapagliflozin is a sodium glucose co transpoter inhibitor 
(antidiabetic drug), which prevents glucose reabsorption in the 
kidney. Thus leads to the elimination of glucose through urine [1-2].  
Various analytical methods have been reported for dapagliflozin alone 
and in combination with metformin hydrochloride. Methods such as UV 
spectroscopy for estimation of dapagliflozin alone or in combination 
with metformin hydrochloride [3-7, 9], HPLC method for estimation of 
dapagliflozin and metformin hydrochloride [8] and alone dapagliflozin in 
API [10], LC MS/MS for dapagliflozin [11] has been reported. 
 
 
Fig. 1: Structure of dapagliflozin from pubmed 
 
However, an extensive literature search didn’t reveal any estimation 
method for dapagliflozin in API and Pharmaceutical dosage form. 
Therefore an attempt has been made to develop and validate simple, 
precise, accurate HPLC method for estimation of dapagliflozin in API 
and Pharmaceutical dosage form. 
MATERIALS AND METHODS 
Drugs, chemicals and solvents: Dapagliflozin in API was kindly given 
by advanced analytical research and training institute, gujarat. All 
the chemicals and solvents used were of analytical grade. 
Instruments 
The analysis was performed on agilent HPLC fitted with a gradient 
pump photo diode array detector and agilent C18 (4.6 mm150,5 µm) 
column which is maintained at an ambient temperature. The 
optimized mobile phase composition was a mixture of acetonitrile: 
dipotassium hydrogen phosphate with pH 6.5 adjusted with OPA 
(40:60 %v/v) with a flow rate of 1 ml/min. The injection volume was 
20 µl. The chromatographic run time was adjusted to 6 min. The 
wavelength of the detector was set at 222 nm for analysis of the drug. 
Preparation of buffer 
Dissolve 0.435 gm (gram) of dipotassium hydrogen phosphate in 
100 ml (milliliter) of HPLC water. Filter the solution through 0.45 µ 
nylon filter. Adjust the pH-6.5 with dilute orthophosphoric acid and 
degas before use. 
Preparation of mobile phase 
Prepare a mixture of buffer (dipotassium hydrogen phosphate) and 
acetonitrile in the ratio of 60:40. Adjust the pH 6.5 with diluted 
ortho phosphoric acid (OPA). This solution was sonicated for 5 min 
(minute) for degassing and filtered through 0.45 µ millipore filter. 
Diluent 
The drug was dissolved in acetonitrile. 
Preparation of standard stock solution (API) 
Accurately weighed 10 mg (milligram) of dapagliflozin was taken in 
a 10 ml standard volumetric flask and dissolved in few ml of 
acetonitrile. Then the volume was made up to the mark with 
acetonitrile. From the above solution, 5 ml was diluted to 10 ml with 
to get a concentration of 500 µg/ml of dapagliflozin. 
Preparation of standard stock solution (tablet) 
The average of 10 tablets was determined and grounded in a mortar. 
An accurately weighed amount of powder equivalent to 10 mg of 
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dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug after sonication, volume was made 
up to the mark with diluents (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluents (500 µg/ml of dapagliflozin). 
Calibration curve 
Aliquots of different concentrations of standard solution were 
prepared and their chromatograms were recorded at the optimized 
chromatographic conditions. The mean peak areas at different 
concentration levels were calculated from the chromatograms. Then 
the linearity plot was constructed using the mean peak areas at their 
respective concentrations fig. 14. 
Forced degradation study 
Forced degradation study of dapagliflozin in API and pharmaceutical 
dosage form was carried out under different stress conditions as 
mentioned in ICH guideline Q1A (R2). The standard solution 
containing 500 µg/ml of dapagliflozin API and 500 µg/ml of 
dapagliflozin tablet were subjected to acid, alkali hydrolysis, 
peroxide, thermal and photolytic degradation. 
Acid degradation 
Transfer 1 ml of standard solution to 10 ml of volumetric flask. Add 
1 ml of 0.1 N HCl keep the volumetric flask in water bath at 60 °C for 
2 h. After time period cool the contents to ambient temperature. 
Neutralized the solution with 1 ml of 0.1 N NaOH and volume was 
made up to 10 ml with diluent. After inject the acid degradation 
sample into HPLC, peak area and peak shapes were observed fig. 2.  
Procedure for tablet 
The average of 10 tablets was determined and grounded in mortar. 
An accurately weighed amount of powder equivalent to 10 mg of 
dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug. After sonication, volume was made 
up to the mark with diluent (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluent (500 µg/ml of dapagliflozin). Pipette out 1 ml from 
the sample solution and add 1 ml of 0.1N HCl and keep at 60 °C in 
water bath for 2 h. After time period cool the contents to ambient 
temperature. Neutralized the solution with 1 ml of 0.1 N NaOH and 
volume was made up to 10 ml with diluents. After inject the acid 
degradation sample into HPLC,peak area and peak shape were 
observed fig. 3. 
Base degradation  
Procedure for API 
Transfer 1 ml of standard solution to 10 ml of volumetric flask. Add 
1 ml of 0.1 N NaOH keep the volumetric flask in a water bath at 60 °C 
for 2 h. After time period cool the contents to ambient temperature. 
Neutrilized the solution with 1 ml of 0.1 N HCl and volume was made 
up to 10 ml with diluents. After inject the base degradation sample 
into HPLC, peak area and peak shape were observed fig. 4. 
Procedure for tablet 
The average of 10 tablet was determined and grounded in mortar. 
An accurately weighed amount of powder equivalent to 10 mg of 
dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug. After sonication, volume was made 
up to the mark with diluent (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluent (500 µg/ml of dapagliflozin). Pipette out 1 ml from 
the sample solution and add 1 ml of 0.1N NaOH and keep at 60 °C in 
water bath for 2 h. After time period cool the contents to ambient 
temperature. Neutralized the solution with 1 ml of 0.1 N HCl and 
volume was made up to 10 ml with diluent. After inject the base 
degradation sample into HPLC, peak area and peak shape were 
observed fig. 5. 
Peroxide degradation 
Procedure for API 
Transfer 1 ml of standard solution to 10 ml of volumetric flask. Add 
1 ml of 3 % H2O2, keep the volumetric flask in a water bath at 60 °C 
for 2 h. After time period cool the contents to ambient temperature. 
Dilute the volume with diluent. After inject the peroxide degradation 
sample into HPLC, peak area and peak shape were observed fig. 6. 
Procedure for tablet 
The average of 10 tablet was determined and grounded in mortar. 
An accurately weigh the amount of powder equivalent to 10 mg of 
dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug. After sonication, volume was made 
up to the mark with diluent (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluent (500 µg/ml of dapagliflozin). Pipette out 1 ml from 
the sample solution and add 1 ml of 3 % H2O2, keep the volumetric 
flask in water bath at 60 °C for 2 h. After time period cool the 
contents to ambient temperature. Dilute the volume with diluent. 
After inject the peroxide degradation sample into HPLC, peak area 
and peak shape were observed fig. 7. 
Thermal degradation 
Procedure for API 
Transfer 1 ml of standard solution to 10 ml of volumetric flask. Keep 
the volumetric flask in water bath at 60 °C for 2 h. After time period 
cool the contents to ambient temperature. Make up the volume with 
diluent. After injecting the thermal degradation sample into HPLC, 
peak area and peak shape were observed fig. 8. 
Procedure for tablet 
The average of 10 tablet was determined and grounded in mortar. 
An accurately weigh the amount of powder equivalent to 10 mg of 
dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug. After sonication, volume was made 
up to the mark with diluents (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluent (500 µg/ml of dapagliflozin). Pipette out 1 ml of the 
sample solution to 10 ml of volumetric flask. Keep the volumetric 
flask in water bath at 60 °C for 2 h. After time period cool the 
contents to ambient temperature. Make up the volume with diluent. 
After inject the thermal degradation sample into HPLC, peak area 
and peak shape were observed fig. 9. 
Photolytic degradation 
Procedure for API 
Transfer 1 ml of standard solution to 10 ml of volumetric flask. It 
was exposed to direct sunlight for 1 h, make up the volume with 
diluent. After inject the photolytic degradation sample into HPLC, 
peak area and peak shape was observed fig. 10. 
Procedure for tablet 
The average of 10 tablet was determined and grounded in mortar. 
An accurately weigh the amount of powder equivalent to 10 mg of 
dapagliflozin was taken. It was transferred to 10 ml of volumetric 
flask. Add 5 ml of diluents and sonicated for 5 min to ensure 
complete solubilization of drug. After sonication, volume was made 
up to the mark with diluents (1000 µg/ml of dapagliflozin stock 
solution). Pipette out 5 ml from above solution and dilute up to 10 
ml with diluents (500 µg/ml of dapagliflozin). Pipette out 1 ml of the 
sample solution to 10 ml of volumetric flask. It was exposed to direct 
sunlight for 1 h, make up the volume with diluent. After inject the 
photolytic degradation sample into HPLC, peak area and peak shape 
were observed fig. 11. 
Method validation 
System suitability was carried out by injecting standard solutions of 
API and tablet 5 times into the chromatographic system. The system 
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suitability parameters were then evaluated for tailing factor, 
retention time and theoretical plates of standard chromatograms. 
Accuracy 
The accuracy of the test method was demonstrated by % recovery 
across its range by making three different concentrations at 50%, 
100% and 150 % level using standard addition method. 
Intraday precision  
Intraday precision was performed by injecting standard 
preparations three times on the day by maintaining the optimized 
chromatographic conditions and calculate % relative standard 
deviation of retention time and peak areas for dapagliflozin. 
Inter-day precision 
Inter-day precision was performed by injecting standard 
preparations three times into chromatographic system on 2 
different days by maintaining the optimized chromatographic 
conditions and calculate % relative standard deviation of retention 
time and peak areas for dapagliflozin. 
Repeatability 
Method precision of experiment was performed by preparing the 
standard solutions of Dapagliflozin (500 µg/ml) for six times and 
analysed as per proposed method and % RSD was calculated. 
Linearity  
Transfer an accurately weighed quantity about 100 mg of 
dapagliflozin in 100 ml volumetric flask, dissolve and dilute the 
volume with diluents. Prepare different linearity concentration 
solutions in the range of 250–750 µg/ml. 
Robustness  
The robustness was studied by analyzing the sample of dapagliflozin 
by deliberate variation in method parameters. The change in 
response of dapagliflozin was noted. Robustness of the method was 
studied by changing flow rate±0.2 ml, mobile phase composition and 
column temperature. The change in the response of dapagliflozin 
was noted and compared with the original one. 
Limit of detection and limit of quantification 
LOD and LOQ were determined by using the formula based on the 
standard deviation of the response and the slope. LOD and LOQ were 
calculated by using equations:  
LOD = 3.3 σ/S 
LOQ = 10 σ/S  
Where, σ = Standard deviation of response 
S = Slope of calibration curve 
RESULTS AND DISCUSSION 
The detection wavelength was carried out in the UV range of 222 
nm. Chromatographic separation was carried out using mobile 
phase composed 1 molar dipotassium hydrogen phosphate and 
acetonitrile (60:40 % v/v) and pH was adjusted to 6.5 with 
orthophophoric acid on agilent C18 (4.6 mm150,5 µm) at a flow rate 
of 1 ml/min using PDA detector. 
 
(1) Acid degradation for API and tablet 
 
Fig. 2: Acid degradation for dapagliflozin in API 
 
 
Fig. 3: Acid degradation for dapagliflozin in tablet 
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(2) Base degradation for API and tablet 
 
Fig. 4: Base degradation for dapagliflozin in API 
 
 
Fig. 5: Base degradation for dapagliflozin tablet 
 
(3) Peroxide degradation 
 
Fig. 6: Peroxide degradation for dapagliflozin API 
 
 
Fig. 7: Peroxide degradation for dapagliflozin tablet 
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(4) Thermal degradation 
 
Fig. 8: Thermal degradation for dapagliflozin API 
 
 
Fig. 9: Thermal degradation for dapagliflozin tablet 
 
(5) Photolytic degradation 
 
Fig. 10: Photolytic degradation for dapagliflozin API 
 
 
Fig. 11: Photolytic degradation for dapagliflozin 
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Tablet 1: Degradation summary for API 
Type Solution Area %Degradation 
As such Dapagliflozin 52331398 - 
Acid 
0.1 N* HCL* at 60 °C for 2 h in water bath Dapagliflozin 3270712 6.25% 
Base 
0.1 N NaOH* at 60 °C for 2 h in water bath Dapagliflozin 27787835 5.31% 
Peroxide 
3% H2O2* at Room Temperature for 3 h Dapagliflozin 5059869 9.66% 
Thermal 
At 60 °C for 3 h Dapagliflozin 6116184 11.68% 
Photolytic 
in sun light for 1 h Dapagliflozin 7849709 9.23% 
N*-normal, HCl*-hydrochloric acid, NaOH*-sodium hydroxide, H2O2*-hydrogen hydroxide 
 
Table 2: Degradation summary for tablet 
Type Solution Area % Degradation 
As such Dapagliflozin 18920313 - 
Acid 











































Fig. 12: Chromatogram of API 
 
Table 3: System suitability results (API) 
S. No. System suitability parameter Results 
1 Tailing 1.28 
2 Retention Time 3.160 min 
3 Plate count 2350 
4 Area 5165316 
5 Correlation coefficient 0.99 
6 LOD* 5.14 µg/ml 
7 LOQ* 15.6 µg/ml 
LOD*-Limit of detection, LOQ*-Limit of quantification 
 
Table 4: System suitability results (tablet) 
S. No. System suitability parameters  Results 
1 Tailing 1.20 
2 Retention time 3.067 
3 Plate count 2030 
4 Area 18920313 
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Fig. 13: Chromatogram of tablet 
 
Table 5: System suitability data 
Parameters Observation Specification 
API Tablet 
% RSD of Area 0.26 0.411 RSD<2% 
Resolution(Rs) 0.00 0.00 Rs>2 
Tailing Factor(T) 1.28±0.04 1.02±0.09 T ≤ 2 
Theoritical plates(N) 2350±185.02 2115.4±200.36 ≥2000 
 
 
Fig. 14: Overlay spectra of dapagliflozin 
 
Table 6: Linearity data for dapagliflozin 
Conc* Peak area±SD* (n=5) %RSD* 
250 5274844.2±11182.6 0.21 
400 8958845.32±10236.58 0.12 
500 11198557.8±30236.23 0.27 
600 13438268.54±50923.2 0.38 
750 16797835.69±99983.5 0.59 
Number of experiment (n)-5, Conc*-concentration, SD*-standard deviation, %RSD*-relative standard deviation 
 
 
Fig. 15: Calibration plot of dapagliflozin 
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Table 7: Accuracy for API and tablet 
Sample Level (%) Amount recovered (µg/ml) Mean % recovery±SD* 
  
Dapagliflozin API 
50  402.96±0.507 99.72±0.12 
100 503.28±0.55  99.65±0.109 
150 601.12±0.24 99.19±0.03 
 
Dapagliflozin tablet 
50 398.65±0.55 98.67±0.13 
100 501.98±0.871 99.40±0.17 
150 605.89±0.98 99.98±0.16 
Number of experiment (n)=3, SD*-standard deviation, precision study results 
 
Table 8: Intraday precision 
Conc* (µg/ml) Area±SD* % RSD* 
400 11304882.67±45662.51 0.40 
500 11205269±27555.81 0.26 
600 11368903.33±23214.27 0.204 
Conc*-concentration, Number of experiment (n)-3, SD*-standard deviation, RSD*-relative standard deviation 
 
Table 9: Interday precision 
Conc* (µg/ml) Area±SD* % RSD* 
400 11386283±25806.57 0.23 
500 11174585.67±46710.12 0.42 
600 11192177±38642.96 0.34 
Conc*-concentration, Number of experiment (n)-3, SD*-standard deviation, RSD*-relative standard deviation 
 
Table 10: Repeatability data 









% RSD* 0.102 
Number of experiment (n)-6, SD*-standard deviation, RSD*-relative standard deviation 
 
Table 11: Robustness study 
Conc*(500 µg/ml) Flow rate Temperature( °C) Mobile Phase 
0.8 ml 1.2 ml 25 ° 35 ° +5 ml -5 ml 
Avg. area 66176464 5234741 1456537.3 1856685 18478292.3 43198353 
SD* 78967.96 5998.1 12044.42 102585 132229.6 20341.1 
% RSD* 0.11 0.11 0.83 0.55 0.83 0.12 
 Conc*-concentration, Number of experiment (n)-3, SD*-standard deviation, RSD*-relative standard deviation 
 
Table 12: LOD and LOQ 
Parameter Dapagliflozin 
LOD* (µg/ml) 5.14 
LOQ* (µg/ml) 15.6 
LOD*-limit of detection, LOQ*-limit of quantification 
 
DISCUSSION 
A new stability indicating RP-HPLC method has been developed for 
estimation of Dapagliflozin in API and Tablet dosage form was rapid, 
accurate, precise, specific, sensitive and robust. 
From the above study, we can conclude that the dapagliflozin was 
subjected to acid, alkali hydrolysis, and oxidation, thermal and 
photolytic degradation. The degradation studies indicate that 
dapagliflozin is more susceptible to thermal degradation and 
Forxiga is more susceptible to photolytic degradation. 
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From the peak purity study, it was confirmed that the peak of 
degradation product and excipient was not interfering with the peak 
of the drug. Hence this method was used for the analysis of 
Dapagliflozin in API and tablet dosage form in quality control 
department for routine analysis. 
Linearity of the developed method follows beer’s law and was near 
to 0.99. It found to be linear in the range 250–750 µg/ml. % RSD was 
found to be less than 2 for precision. The method is robust since by 
deliberate variation in method, % RSD was found to be less than 2. 
So the is found to be robust. 
% Recoveries was found to be 99.65 %. Hence this method can be 
used for analysis of dapagliflozinin API and Tablet dosage form in 
quality control department for routine analysis. 
CONCLUSION 
In the present study, we have developed a new, rapid RP-HPLC 
method and validated for different parameters (system suitability, 
linearity, accuracy, precision, LOD, LOQ robustness). By studying all 
these we have concluded that the method was linear, accurate, 
precise, robust and rapid for determination of dapagliflozin in API 
and Pharmaceutical dosage form. Hence the method was 
successfully applied for the estimation of dapagliflozin in API and 
Pharmaceutical dosage form. 
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